Skip to main content
SpringerLink
Log in

L-Deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors

  • Original Articles
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Previously, we have reported thatL-deprenyl decreased the incidence of mammary tumors and pituitary tumors in old acyclic rats. The objective of the present study was to investigate the effects ofL-deprenyl, a monoamine oxidase-B (MAO-B) inhibitor, treatment on the development and growth of tumors and on the metabolism of catecholamines and indoleamine in the medial basal hypothalamus (MBH) and the striatum (ST) of rats bearing 7,12-dimethylbenzanthracene (DMBA)-induced mammary tumors. Female Sprague-Dawley rats with DMBA-induced mammary tumors were injected (sc) daily with 0.25 mg or 5.0 mg of deprenyl/kg BW or the vehicle (saline; control) for 12 wk. Tumor diameter, tumor number, body weight, and feed intake were measured every week of the treatment period. Serum PRL and the concentrations of catecholamines, indoleamine, and their metabolites were measured by RIA and HPLC, respectively. Treatment with 5.0 mg deprenyl decreased the tumor diameter, tumor number,and serum prolactin (PRL) level. Although the body weight increased in all three groups, the body weight gain in the 5.0 mg group was smaller than that in the control and 0.25 mg groups. Deprenyl treatment had no effect on feed intake. The concentrations of dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were decreased in the MBH and the ST, and the concentration of 5-hydroxy-indoleacetic acid (5-HIAA) was decreased in the MBH of deprenyl-treated rats. Treatment with 5.0 mg deprenyl enhanced the concentrations of norepinephrine (NE) and serotonin (5-HT) in the MBH and in the ST, and the concentration of dopamine (DA) in the MBH. These results suggest that the suppression of the development and growth of DMBA-induced mammary tumors by chronic deprenyl treatment may be mediated through alterations in the synthesis and metabolism of catecholamines and indoleamine in the MBH and inhibition of PRL secretion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Birkmayer, W., Knoll, J., Riederer, P., and Youdim, M. B. H. (1983).Mod. Probl. Pharmacopsychiatry 19, 170–176.

    PubMed  CAS  Google Scholar 

  2. Tariot, P. N., Sunderland, T., Weingartner, H., Murphy, D. L., Welkowitz, J.A., Thompson, K., and Cohen, R. M. (1987).Psychopharmacology 91, 489–495.

    Article  PubMed  CAS  Google Scholar 

  3. Knoll, J., Dallo, J., and Yen, T. T. (1989).Life Sci. 45, 525–532.

    Article  PubMed  CAS  Google Scholar 

  4. Milgram, N. W., Racine, R. J., Nellis, P., Mendonca, A., and Ivy, G. O. (1990).Life Sci. 47, 415–420.

    Article  PubMed  CAS  Google Scholar 

  5. Brandeis, R., Sapir, M., Kapon, Y., Borelli, G., Cadel, S., and Valsecchi, B. (1991).Pharmacol. Biochem. Behav. 39, 297–304.

    Article  PubMed  CAS  Google Scholar 

  6. Knoll, J. (1988).Mech. Ageing Dev. 46, 237–262.

    Article  PubMed  CAS  Google Scholar 

  7. Meites, J. (1982).Neuroendocrinology 34, 151–156.

    PubMed  CAS  Google Scholar 

  8. MohanKumar, P. S., ThyagaRajan, S., and Quadri, S. K. (1994).Endocrinology 135, 119–126.

    Article  PubMed  CAS  Google Scholar 

  9. ThyagaRajan, S., MohanKumar, P. S., and Quadri, S. K. (1995).Brain Res. 689, 122–128.

    Article  PubMed  CAS  Google Scholar 

  10. MohanKumar, P. S., ThyagaRajan, S., and Quadri, S. K. (1995).Brain. Res. Bull. 38, 561–564.

    Article  PubMed  CAS  Google Scholar 

  11. MohanKumar, P. S., ThyagaRajan, S., and Quadri, S. K. (1997).Brain Res. Bull. 42, 265–271.

    Article  PubMed  CAS  Google Scholar 

  12. Meites, J. (1980).J. Neural Transm. 48, 25–42.

    Article  PubMed  CAS  Google Scholar 

  13. Quadri, S. K., Kledzik, G. S., and Meites, J. (1973).Proc. Soc. Exp. Biol. Med. 142, 759–761.

    PubMed  CAS  Google Scholar 

  14. Quadri, S. K., Clark, J. L., and Meites, J. (1973).Proc. Soc. Exp. Biol. Med. 142, 22–26.

    PubMed  CAS  Google Scholar 

  15. Leung, F. C., Aylsworth, C. F., and Meites, J. (1983).Proc. Soc. Exp. Biol. Med. 173, 159–163.

    PubMed  CAS  Google Scholar 

  16. ThyagaRajan, S., Meites, J., and Quadri, S. K. (1993).Proc. Soc. Exp. Biol. Med. 203, 236–242.

    PubMed  CAS  Google Scholar 

  17. ThyagaRajan, S., Meites, J., and Quadri, S. K. (1995).Endocrinology 136, 1103–1110.

    Article  PubMed  CAS  Google Scholar 

  18. MohanKumar, P. S., Meites, J., and Quadri, S. K. (1994).Life Sci. 54, 841–845.

    Article  PubMed  CAS  Google Scholar 

  19. Welsch, C. W. and Nagasawa, H. (1977).Cancer Res.,37, 951–963.

    PubMed  CAS  Google Scholar 

  20. ThyagaRajan, S., Felten, S. Y., and Felten, D. L. (1998).Cancer Lett. 123, 177–183.

    Article  PubMed  CAS  Google Scholar 

  21. Demarest, K. T. and Moore, K. E. (1979).J. Neural Transm. 46, 263–277.

    Article  PubMed  CAS  Google Scholar 

  22. Gudelsky, G. A. and Metzer, H. Y. (1984).Neuroendocrinology 38, 51–55.

    PubMed  CAS  Google Scholar 

  23. MohanKumar, P. S. and Quadri, S. K. (1992). 9th International Congress of Endocrinology, Nice, France, 555 (Abstract).

  24. ThyagaRajan, S. and Quadri, S. K. (1992). 74th Annual Meeting of the Endocrine Society, San Antonio, TX, 431 (Abstract).

  25. Dickson, R. B. and Lippman, M. E. (1992).Semin. Oncol. 19, 286–298.

    PubMed  CAS  Google Scholar 

  26. Szepeshazi, K., Milovanovic, S., Lapis, K., Groot, K., and Schally, A. V. (1992).Breast Cancer Res. Treat. 21, 181–192.

    Article  PubMed  CAS  Google Scholar 

  27. Bartke, A., Cecim, M., Tang, K., Steger, R. W., Chandrashekar, V., and Turyn, D. (1994).Proc. Soc. Exp. Biol. Med. 206, 345–359.

    PubMed  CAS  Google Scholar 

  28. ThyagaRajan, S., Madden, K. S., Kalvass, J. C., Dimitrova, S., Felten, S. Y., and Felten, D. L. (1998).J. Neuroimmunol. 92, 9–21.

    Article  PubMed  CAS  Google Scholar 

  29. Yang, H-Y. T. and Neff, H. (1974).J. Pharmacol. Exp. Ther. 189, 733–740.

    PubMed  CAS  Google Scholar 

  30. Green, A. R., Mitchell, B. D., Tordoff, A. F. C., and Youdim, M. B. H. (1977).Br. J. Pharmacol. 60, 343–349.

    PubMed  CAS  Google Scholar 

  31. Ekstedt, B., Magyar, K., and Knoll, J. (1979).Biochem. Pharmacol. 28, 919–923.

    Article  PubMed  CAS  Google Scholar 

  32. Waldmeier, P. C. and Felner, A. E. (1979).Biochem. Pharmacol. 27, 801–802.

    Article  Google Scholar 

  33. Heinonen, E. H., Antilla, M. I., and Lammintausta, R. A. S. (1994).Clin. Pharmacol. Ther. 56, 742–749.

    Article  PubMed  CAS  Google Scholar 

  34. Nickel, B., Szelenyi, I., and Schulze, G. (1994).Clin. Pharmacol. Ther. 56, 757–767.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroendocrine Research Laboratory, Kansas State University, Manhattan, KS

    Srinivasan ThyagaRajan Ph. D. & S. Kaleem Quadri

Authors
  1. Srinivasan ThyagaRajan Ph. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Kaleem Quadri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Srinivasan ThyagaRajan Ph. D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

ThyagaRajan, S., Quadri, S.K. L-Deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors. Endocr 10, 225–232 (1999). https://doi.org/10.1007/BF02738621

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02738621

Key Words

Search

Navigation